Specialized pro-resolving mediator (SPM)-enriched supplementation modulates inflammatory biomarkers in patients with symptomatic knee osteoarthritis: Blood plasma analysis from the GAUDI study
Prostaglandins, Leukotrienes and Essential Fatty Acids · 2026-10 · 210 · 102758
DOI: 10.1016/j.plefa.2026.102758 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Prostaglandins, Leukotrienes and Essential Fatty Acids, 2026-10. Verfasst von Ingrid Möller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institut Poal de Reumatología, Barcelona, Spain. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Dietary Supplements, Docosahexaenoic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Queen Mary University of London.
Abstract (Originalsprache)
BACKGROUND: Osteoarthritis (OA) is a leading cause of chronic pain and functional impairment, associated with persistent inflammation, potentially due to impaired resolution. Specialized pro-resolving lipid mediators (SPMs) regulate inflammation resolution and restore homeostasis. The GAUDI study previously demonstrated that SPM supplementation reduces pain and improves quality of life (QoL) in patients with knee OA. This analysis assesses the impact of SPM supplementation on inflammatory biomarkers (IB) and SPM levels and their relationship with clinical outcomes. METHODS: This is a secondary analysis of the GAUDI trial, a randomized, multicenter, double-blind, placebo-controlled study conducted in Spain in adults with symptomatic knee OA who received daily supplementation with SPMs or placebo for 12 weeks. Endpoints included changes in plasma IB and SPM levels and their correlation with clinical outcomes. RESULTS: Changes in IL-1 (15.9 vs. -1.1 pg/ml, p-value: 0.051) and IL-18 (10.3 vs. -1.4 pg/ml, p-value: 0.29) showed a tendency toward reduction in the SPM group compared to the placebo group. Changes in IL-1 and IL-8 positively correlated (r = 0.707, p-value: 0.005 and r = 0.551, p-value: 0.04; respectively) with changes in WOMAC score and negatively correlated (r = -0.797, p-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Poal de Reumatología, Barcelona, Spain.
- FC Barcelona Medical Department, Barcelona, Spain.
- FC Atlético de Madrid Medical Department, Madrid, Spain.
- Asturias Football Federation, Avilés, Spain.
- Athletic FC, Bilbao, Spain.
- Osteoarthritis Foundation International (OAFI), Barcelona, Spain.
Förderung
- Queen Mary University of London
Zitieren
APA
Möller, I., Rodas, G., Villalón, J. M., Rodas, J. A., Angulo, F., Martínez, N., & Vergés, J. (2026). Specialized pro-resolving mediator (SPM)-enriched supplementation modulates inflammatory biomarkers in patients with symptomatic knee osteoarthritis: Blood plasma analysis from the GAUDI study. Prostaglandins, Leukotrienes and Essential Fatty Acids, 210, 102758. https://doi.org/10.1016/j.plefa.2026.102758
Vancouver
Möller I, Rodas G, Villalón JM, Rodas JA, Angulo F, Martínez N, et al. Specialized pro-resolving mediator (SPM)-enriched supplementation modulates inflammatory biomarkers in patients with symptomatic knee osteoarthritis: Blood plasma analysis from the GAUDI study. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2026;210:102758. doi:10.1016/j.plefa.2026.102758
BibTeX
@article{Mller2026,
author = {Möller, Ingrid and Rodas, Gil and Villalón, Jose María and Rodas, Jose A and Angulo, Francisco and Martínez, Nina and Vergés, Josep},
title = {Specialized pro-resolving mediator (SPM)-enriched supplementation modulates inflammatory biomarkers in patients with symptomatic knee osteoarthritis: Blood plasma analysis from the GAUDI study},
journal = {Prostaglandins, Leukotrienes and Essential Fatty Acids},
year = {2026},
volume = {210},
pages = {102758},
doi = {10.1016/j.plefa.2026.102758}
}
EUVIMED